Pruxelutamide is under clinical development by Kintor Pharmaceutical and currently in Phase II for Hormone-Sensitive Prostate Cancer. According to GlobalData, Phase II drugs for Hormone-Sensitive Prostate Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pruxelutamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pruxelutamide overview
Proxalutamide (GT-0918) is under development for the treatment of Coronavirus COVID-19 disease, metastatic hormone-sensitive prostate cancer, hormone senstive, castration resistant prostate cancer (CRPC) and AR positive metastatic breast cancer, HER-2 negative breast cancer. It is administered through oral and formulated in the form of tablet. The drug candidate acts by targeting androgen receptor. It was also under development for triple negative breast cancer.
Kintor Pharmaceutical overview
Kintor Pharmaceutical (Kintor) is a clinical stage drug company. The company’s pipeline products include KX-826 and AR-PROTAC (GT20029) is for the treatment of androgenetic alopecia (male), androgenetic alopecia (female), androgenetic alopecia (male), androgenetic alopecia (long-term safety), combined with minoxidil for androgenetic alopecia (male), acne vulgaris, acne vulgaris; pruxelutamide (GT0918) treats COVID-19; GT1708F1 targets idiopathic pulmonary fibrosis (IPF) and blood cancer; GT0486 for metastatic solid tumors; ALK-1 (GT90001) is for the treatment of combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC), angiogenesis inhibitor combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC), combination therapy with a PD-1 for metastatic hepatocellular carcinoma (HCC). The company operates in Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Pruxelutamide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
